OBIO
Income statement / Annual
Last year (2025), Orchestra BioMed Holdings Inc's total revenue was $33.48 M,
an increase of 1,169.22% from the previous year.
In 2025, Orchestra BioMed Holdings Inc's net income was -$52.70 M.
See Orchestra BioMed Holdings Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$33.48 M |
$2.64 M |
$2.76 M |
$3.53 M |
-$782.00 K |
$5.70 M |
| Cost of Revenue |
$190.00 K
|
$204.00 K
|
$186.00 K
|
$322.00 K
|
$199.00 K
|
$145.00 K
|
| Gross Profit |
$33.29 M
|
$2.43 M
|
$2.57 M
|
$3.21 M
|
-$981.00 K
|
$5.56 M
|
| Gross Profit Ratio |
0.99
|
0.92
|
0.93
|
0.91
|
1.25
|
0.97
|
| Research and Development Expenses |
$58.19 M
|
$42.80 M
|
$33.82 M
|
$21.95 M
|
$12.89 M
|
$13.48 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.91 M
|
$23.93 M
|
$20.26 M
|
$13.92 M
|
$7.93 M
|
$10.83 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$85.10 M
|
$66.74 M
|
$54.08 M
|
$35.87 M
|
$20.82 M
|
$24.31 M
|
| Cost And Expenses |
$85.29 M
|
$66.94 M
|
$54.27 M
|
$36.19 M
|
$21.02 M
|
$24.46 M
|
| Interest Income |
$0.00
|
$3.36 M
|
$3.85 M
|
$50.00 K
|
$0.00
|
$331.00 K
|
| Interest Expense |
$1.15 M
|
$0.00
|
$0.00
|
$0.00
|
$927.00 K
|
$0.00
|
| Depreciation & Amortization |
$327.00 K
|
$308.00 K
|
$287.00 K
|
$222.00 K
|
$181.00 K
|
$137.00 K
|
| EBITDA |
-$51.23 M |
-$60.72 M |
-$48.83 M |
-$33.39 M |
-$21.91 M |
-$18.62 M |
| EBITDA Ratio |
-1.53
|
-23.02
|
-17.69
|
-9.45
|
28.01
|
-3.26
|
| Operating Income Ratio |
-1.55
|
-24.37
|
-18.66
|
-9.24
|
27.88
|
-3.29
|
| Total Other Income/Expenses Net |
-$894.00 K
|
$3.28 M
|
$2.39 M
|
-$951.00 K
|
-$1.22 M
|
-$2.60 M
|
| Income Before Tax |
-$52.70 M
|
-$61.02 M
|
-$49.12 M
|
-$33.61 M
|
-$23.01 M
|
-$21.36 M
|
| Income Before Tax Ratio |
-1.57
|
-23.13
|
-17.8
|
-9.51
|
29.43
|
-3.74
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$52.70 M
|
-$61.02 M
|
-$49.12 M
|
-$33.61 M
|
-$23.01 M
|
-$21.36 M
|
| Net Income Ratio |
-1.57
|
-23.13
|
-17.8
|
-9.51
|
29.43
|
-3.74
|
| EPS |
-1.38 |
-1.66 |
-1.48 |
-1.32 |
-0.0185 |
-0.0085 |
| EPS Diluted |
-1.38 |
-1.66 |
-1.48 |
-1.32 |
-0.0185 |
-0.0085 |
| Weighted Average Shares Out |
$38.39 M
|
$36.82 M
|
$33.23 M
|
$25.47 M
|
$20.45 M
|
$20.45 M
|
| Weighted Average Shares Out Diluted |
$38.39 M
|
$36.82 M
|
$33.23 M
|
$25.47 M
|
$20.45 M
|
$20.45 M
|
| Link |
|
|
|
|
|
|
